Drugmakers face threats to protecting their patents in India as a government-appointed panel prepares to evaluate more drugs in order to allow local firms to make low-priced generics.
Among the therapies the committee is preparing to study or had an early look at are two diabetes drugs, Merck’s sitagliptin medication, Januvia, and Bristol-Myers’ saxagliptin drug called Onglyza; Merck’s HIV drug raltegravir, sold under the brand name Isentress; and Bristol-Myers’ arthritis drug abatacept, sold as Orencia, according to Bloomberg sources.
Read the Bloomberg press release